Cartesian Therapeutics Reports 95% Revenue Decline in Q3 2025

Cartesian Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $1.85 million, a significant decrease of 95% compared to $39.67 million in the same period last year. The decline was primarily attributed to a sharp drop in collaboration and license revenue, which fell from $39.11 million to $400,000, largely due to the absence of milestone payments from its partnership with Swedish Orphan Biovitrum AB (Sobi) and the termination of the Astellas Agreement. In contrast, grant revenue increased to $1.45 million from $561,000, reflecting funding received from the National Institute of Neurological Disorders and Stroke.

The company reported a net loss of $37.73 million for the nine months ended September 30, 2025, a 44% improvement from a net loss of $67.17 million during the same period in 2024. This reduction in losses was driven by a favorable change in the fair value of the contingent value right liability, which resulted in a gain of $18.75 million compared to a loss of $51.90 million in the prior year. Operating expenses for the nine months increased by 17% to $66.62 million, primarily due to heightened research and development costs associated with the ongoing Phase 3 trial of its lead product candidate, Descartes-08, for myasthenia gravis.

In terms of operational metrics, Cartesian Therapeutics had cash, cash equivalents, and restricted cash totaling $145.1 million as of September 30, 2025, down from $214.3 million at the end of 2024. The company has indicated that this cash position is expected to fund its operations for at least the next 12 months. The headcount was significantly reduced by approximately 90% in April 2023 as part of a restructuring plan aimed at extending the company's cash runway and focusing on key product candidates.

Looking ahead, Cartesian Therapeutics remains focused on advancing its clinical programs, particularly Descartes-08, while managing its financial resources prudently. The company anticipates continued operating losses as it invests in research and development, and it may seek additional funding through equity offerings or collaborations to support its operations. The management has expressed confidence that its existing cash resources will be sufficient to meet its operational needs in the near term, although it acknowledges the potential need for further capital to sustain its long-term growth strategy.